Currently, the common study end-points in intervention trials for T1D with LD IL-2 administration are clinical remission defined by preservation of C-peptide, decreased level of HbA1c, decreased insulin requirement, normal blood glucose, absence or reduced adverse events including vascular leak syndrome (VLS), serious infections, and allergic reactions, increased counts of eosinophils and neutrophils, and expansion of Tregs (15, 16). This evidence concerns the gene IL2 and type 1 diabetes mellitus.